Assess whether RWE can replace or only supplement an RCT (b62c23)

Situation

A CRL citing manufacturing, not efficacy put advisory-committee question list that exposes a weak secondary endpoint in front of labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT. This Pharma & Life Sciences / Clinical and Evidence Strategy close is RWE can replace or from advisory-committee question list that exposes a weak secondary endpoint, and the live options are RWE can replace, Only supplement an RCT.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Advisory-committee question list that exposes a weak secondary endpoint reads as RWE can replace once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population.
• Advisory-committee question list that exposes a weak secondary endpoint is closer to Only supplement an RCT after a CRL citing manufacturing, not efficacy; RWE can replace would over-claim this Clinical and Evidence Strategy extract.
• A dual reading is still live in advisory-committee question list that exposes a weak secondary endpoint for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.
• Advisory-committee question list that exposes a weak secondary endpoint is missing the fact labeling negotiator needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

Analysis required

• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a CRL citing manufacturing, not efficacy.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a CRL citing manufacturing, not efficacy and write the one fact that would move RWE can replace or for labeling negotiator.